Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Possis’ XVG

This article was originally published in The Gray Sheet

Executive Summary

Full U.S. launch of 5 Fr catheter to remove blood clots from peripheral arteries greater than or equal to 3 mm commences April 29. The 510(k)-cleared catheter becomes the highest power catheter in the firm's product line and will be used for large, distal vessels and older clot burdens, the company says. Possis recently submitted a PMA supplement to expand the XVG's indications for use in coronary saphenous vein grafts and native conduits. The catheter will be sold at a slight premium to the firm's XMI catheter, based on its versatility...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT016516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel